- From
- Russia
- Hospital for treatment
- Jiahui International Hospital, Shanghai
- Disease
- Relapsed and refractory multiple myeloma
- Treatment/medical stage
- CAR-T cell therapy
Treatment options after repeated relapse
Russian professor Vladimir Borzenkov suffers from high-risk multiple myeloma. He has received multiple lines of drug treatment and two autologous hematopoietic stem cell transplants, but the disease still relapses. A Russian hematologist introduced him to CAR-T; a Chinese student’s suggestion allowed him to learn more about the treatment resources in Chinese hospitals.
Communicate about the condition before coming to China
Dr. Li Hua from Jiahui Hematology Department communicates remotely with the patient and evaluates subsequent treatment based on the information provided by Russian doctors. The first step in cross-border medical treatment is to sort out past treatment history, clarify the disease status, and then confirm whether the patient is eligible for further treatment.
Cell collection, reinfusion and observation
In December 2023, the patient completed cell collection; in January 2024, he received CAR-T infusion. Grade 1 cytokine release syndrome occurred on day 4 after reinfusion, and was treated and observed by the medical team. He was discharged from the hospital approximately 13 days after the reinfusion and later returned to Russia for follow-up.
Results at time of reporting
Wen Wei Po reported in May 2024 that the patient achieved complete remission at the latest follow-up at that time. This is an evaluation of efficacy at a specific time point, and the disease status still needs to be reviewed later. This case presents the complete path of cooperation between overseas attending doctors and the Shanghai team, and return to the home country for follow-up after treatment.
Report source
- 来自
- 俄罗斯
- 就诊医院
- 上海嘉会国际医院
- 疾病
- 复发难治性多发性骨髓瘤
- 治疗／就医阶段
- CAR-T 细胞治疗
反复复发后的治疗选择
俄罗斯教授 Vladimir Borzenkov 患有高危多发性骨髓瘤，曾接受多线药物治疗和两次自体造血干细胞移植，疾病仍然复发。俄罗斯血液科医生向他介绍了 CAR-T；一位中国学生的建议，让他进一步了解中国医院的治疗资源。
来华之前先沟通病情
嘉会血液科李华医生与患者开展远程沟通，并结合俄罗斯医生提供的资料评估后续治疗。跨境就医的第一步是整理既往治疗史、明确疾病状态，再确认患者是否具备进一步接受治疗的条件。
细胞采集、回输与观察
2023 年 12 月，患者完成细胞采集；2024 年 1 月接受 CAR-T 回输。回输后第 4 天出现 1 级细胞因子释放综合征，医疗团队进行处理与观察。他在回输约 13 天后出院，之后回俄罗斯接受随访。
报道时的结果
文汇报 2024 年 5 月的报道指出，患者在当时的最新随访中达到完全缓解。这是特定时间点的疗效评估，后续仍需复查疾病状态。该案例呈现了海外主治医生与上海团队协作、治疗后回本国随访的完整路径。